Today, the U.S. Food and Drug Administration has approved a new subcutaneous formulation of Benlysta (belimumab) for subcutaneous use (SC), providing a new, less invasive method for administering this ...
The 200mg single-dose prefilled autoinjector allows pediatric patients to receive SLE treatment at home via SC administration. The Food and Drug Administration (FDA) has approved Benlysta (belimumab) ...
The European Commission has approved a new subcutaneous formulation of belimumab (Benlysta, GlaxoSmithKline) as adjunctive treatment for adults with active, autoantibody-positive systemic lupus ...
The European Medicines Agency (EMA) has recommended approval of a self-injectable form of belimumab (Benlysta, GlaxoSmithKline) as an add-on therapy for adults with the most common form of lupus, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback